These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27805825)

  • 1. Skin sensitisation, adverse outcome pathways and alternatives.
    Basketter D
    Altern Lab Anim; 2016 Oct; 44(5):431-436. PubMed ID: 27805825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIMES-SS--recent refinements resulting from an industrial skin sensitisation consortium.
    Patlewicz G; Kuseva C; Mehmed A; Popova Y; Dimitrova G; Ellis G; Hunziker R; Kern P; Low L; Ringeissen S; Roberts DW; Mekenyan O
    SAR QSAR Environ Res; 2014; 25(5):367-91. PubMed ID: 24785905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Building confidence in skin sensitisation potency assessment using new approach methodologies: report of the 3rd EPAA Partners Forum, Brussels, 28th October 2019.
    Basketter D; Beken S; Bender H; Bridges J; Casati S; Corvaro M; Cuvellier S; Hubesch B; Irizar A; Jacobs MN; Kern P; Lamplmair F; Manou I; Müller BP; Roggeband R; Rossi LH
    Regul Toxicol Pharmacol; 2020 Nov; 117():104767. PubMed ID: 32866543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitisation potency. Part 2. The biological variability of the murine Local Lymph Node Assay (LLNA) for skin sensitisation.
    Roberts DW; Api AM; Aptula AO
    Regul Toxicol Pharmacol; 2016 Oct; 80():255-9. PubMed ID: 27470439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of a systems biology approach to skin allergy risk assessment.
    Maxwell G; Mackay C
    Altern Lab Anim; 2008 Nov; 36(5):521-56. PubMed ID: 19025322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical applicability domain of the local lymph node assay (LLNA) for skin sensitisation potency. Part 4. Quantitative correlation of LLNA potency with human potency.
    Roberts DW; Api AM
    Regul Toxicol Pharmacol; 2018 Jul; 96():76-84. PubMed ID: 29730445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical applicability domain of the Local Lymph Node Assay (LLNA) for skin sensitisation potency. Part 3. Apparent discrepancies between LLNA and GPMT sensitisation potential: False positives or differences in sensitivity?
    Roberts DW; Schultz TW; Api AM
    Regul Toxicol Pharmacol; 2016 Oct; 80():260-7. PubMed ID: 27477089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Skin sensitisation: the Colipa strategy for developing and evaluating non-animal test methods for risk assessment.
    Maxwell G; Aeby P; Ashikaga T; Bessou-Touya S; Diembeck W; Gerberick F; Kern P; Marrec-Fairley M; Ovigne JM; Sakaguchi H; Schroeder K; Tailhardat M; Teissier S; Winkler P
    ALTEX; 2011; 28(1):50-5. PubMed ID: 21311850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative evaluation of in vitro skin sensitisation tests: the human cell-line activation test (h-CLAT) versus the local lymph node assay (LLNA).
    Ashikaga T; Sakaguchi H; Sono S; Kosaka N; Ishikawa M; Nukada Y; Miyazawa M; Ito Y; Nishiyama N; Itagaki H
    Altern Lab Anim; 2010 Aug; 38(4):275-84. PubMed ID: 20822320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction, refinement and replacement: putting the immune system to work.
    Kimber I
    Altern Lab Anim; 2002; 30(6):569-77. PubMed ID: 12511192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A future approach to measuring relative skin sensitising potency: a proposal.
    Jowsey IR; Basketter DA; Westmoreland C; Kimber I
    J Appl Toxicol; 2006; 26(4):341-50. PubMed ID: 16773645
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of non-animal methods for assessing skin sensitisation hazard: A Bayesian Value-of-Information analysis.
    Leontaridou M; Gabbert S; Van Ierland EC; Worth AP; Landsiedel R
    Altern Lab Anim; 2016 Jul; 44(3):255-69. PubMed ID: 27494625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skin sensitization testing in potency and risk assessment.
    Kimber I; Basketter DA; Berthold K; Butler M; Garrigue JL; Lea L; Newsome C; Roggeband R; Steiling W; Stropp G; Waterman S; Wiemann C
    Toxicol Sci; 2001 Feb; 59(2):198-208. PubMed ID: 11158712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probabilistic hazard assessment for skin sensitization potency by dose-response modeling using feature elimination instead of quantitative structure-activity relationships.
    Luechtefeld T; Maertens A; McKim JM; Hartung T; Kleensang A; Sá-Rocha V
    J Appl Toxicol; 2015 Nov; 35(11):1361-1371. PubMed ID: 26046447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A defined approach for predicting skin sensitisation hazard and potency based on the guided integration of in silico, in chemico and in vitro data using exclusion criteria.
    Macmillan DS; Chilton ML
    Regul Toxicol Pharmacol; 2019 Feb; 101():35-47. PubMed ID: 30439387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin sensitisation testing--new perspectives and recommendations.
    Steiling W; Basketter D; Berthold K; Butler M; Garrigue JL; Kimber I; Lea L; Newsome C; Roggeband R; Stropp G; Waterman S; Wiemann C
    Food Chem Toxicol; 2001 Apr; 39(4):293-301. PubMed ID: 11295477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An integrated decision-tree testing strategy for skin sensitisation with respect to the requirements of the EU REACH legislation.
    Grindon C; Combes R; Cronin MT; Roberts DW; Garrod JF
    Altern Lab Anim; 2008 Oct; 36 Suppl 1():75-89. PubMed ID: 19025333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Accounting for data variability, a key factor in in vivo/in vitro relationships: application to the skin sensitization potency (in vivo LLNA versus in vitro DPRA) example.
    Dimitrov S; Detroyer A; Piroird C; Gomes C; Eilstein J; Pauloin T; Kuseva C; Ivanova H; Popova I; Karakolev Y; Ringeissen S; Mekenyan O
    J Appl Toxicol; 2016 Dec; 36(12):1568-1578. PubMed ID: 27080242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The adverse outcome pathway for skin sensitisation: Moving closer to replacing animal testing.
    Schultz TW; Dimitrova G; Dimitrov S; Mekenyan OG
    Altern Lab Anim; 2016 Oct; 44(5):453-460. PubMed ID: 27805828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assuring consumer safety without animal testing: a feasibility case study for skin sensitisation.
    Maxwell G; Aleksic M; Aptula A; Carmichael P; Fentem J; Gilmour N; Mackay C; Pease C; Pendlington R; Reynolds F; Scott D; Warner G; Westmoreland C
    Altern Lab Anim; 2008 Nov; 36(5):557-68. PubMed ID: 19025323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.